Business
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose e
About this update from Acrivon Therapeutics, Inc.
[{"type":"image","alt":"Acrivon Therapeutics, Inc","displaySize":"","headline":null,"caption":"Acrivon Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/18842H0LzLmEExp9Uy8VVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/30d85aaf0ff4222a9289e1cb227420f6","width":300,"height":160}},"lazy":false},{"type":"text","content":"Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy","length":157,"tagName":"p"},{"type":"text","content":"Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy","length":339,"tagName":"p"},{"type":"text","content":"Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose","length":165,"tagName":"p"},{"type":"text","content":"AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics","length":171,"tagName":"p"},{"type":"text","content":"Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology","length":247,"tagName":"p"},{"type":"text","content":"Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027","length":148,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision oncology medicines utilizing its proprietary Generative P...